EC Neurology

Acute transverse myelitis (TM) is an inflammatory condition that presents with quickly advancing motor, sensory, and autonomic symptoms, which can have severe consequences. The three leading causes of acute TM are demyelinating diseases, infections, and autoimmune inflammatory conditions like systemic lupus erythematosus (SLE). The American College of Rheumatology (ACR) includes TM as one of the 19 neuropsychiatric conditions linked with SLE, with an incidence rate of about 1 - 2% among SLE cases. Misdiagnosis is common, often resulting in high morbidity and mortality. This report examines the case of a 23-year-old woman with progressive muscle weakness in her lower limbs, dysesthesias from the abdomen to the feet, and loss of sphincter control. On examination, severe paraparesis with sensory level at T8 was identified. MRI of the thoracolumbar spine showed hyperintensity on T2 and STIR sequences from T7 to L1, consistent with TM. Due to resistance to initial treatment, cyclophosphamide was administered. After a week in the hospital, the patient showed partial neurological improvement. Recognizing TM in SLE patients requires high clinical suspicion, and early intervention is crucial to minimize severe complications and reduce the rates of morbidity and mortality.

 Keywords: Transverse Myelitis; Neuropsychiatric Lupus; Cyclophosphamide; Autoimmune

1. Zhang S., et al. “Clinical features of transverse myelitis associated with systemic lupus erythematosus”. Lupus 4 (2020): 389-397.
2. “The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes”. Arthritis and Rheumatology 4 (1999): 599-608.
3. Fernández-Ávila DG., et al. “Prevalence of systemic lupus erythematosus in Colombia: data from the national health registry 2012-2016”. Lupus10 (2019): 1273-1278.
4. Birnbaum J., et al. “Distinct subtypes of myelitis in systemic lupus erythematosus”. Arthritis and Rheumatology 11 (2009): 3378-3387.
5. Fujieda Y. “Diversity of neuropsychiatric manifestations in systemic lupus erythematosus”. Immunological Medicine4 (2020): 135-141.
6. Rivas-Larrauri F and Yamazaki-Nakashimada MA. “Systemic lupus erythematosus: Is it one disease?” Reumatología Clínica 5 (2016): 274-281.
7. Beh SC., et al. “Transverse myelitis”. Neurologic Clinics 1 (2013): 79-138.
8. Hryb JP., et al. “Myelitis in systemic lupus erythematosus: clinical features, immunological profile and magnetic resonance imaging of five cases”. Spinal Cord Series and Cases 2 (2016): 16005.
9. Katsiari CG., et al. “Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation”. European Journal of Neurology 4 (2011): 556-563.
10. Mader S., et al. “Understanding the antibody repertoire in neuropsychiatric systemic lupus erythematosus and neuromyelitis optica spectrum disorder: do they share common targets?” Arthritis and Rheumatology 2 (2018): 277-286.
11. Tan CT., et al. “International consensus diagnostic criteria for neuromyelitis optica spectrum disorders”. Neurology5 (2016): 491-492.
12. Chiganer EH., et al. “Myelitis and lupus: clinical manifestations, diagnosis and treatment”. Reumatología Clínica 6 (2017): 344-348.
13. Padmanabhan A., et al. “Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue”. Journal of Clinical Apheresis 3 (2019): 171-354.
14. David T., et al. “O17 Effectiveness of rituximab in the treatment of neuro-psychiatric SLE: results from the British Isles Lupus Assessment Group Biologics Register”. Rheumatology1 (2021).